Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBT Margin: 2019-2025

Historic EBT Margin for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to -61.03%.

  • Keros Therapeutics' EBT Margin rose 1358742.00% to -61.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.84%, marking a year-over-year increase of 2887400.00%. This contributed to the annual value of -5,269.10% for FY2024, which is 9605011.00% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' EBT Margin is -61.03%, which was up 66.32% from -181.19% recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EBT Margin ranged from a high of 2,033,500.00% in Q3 2021 and a low of -541,000.00% during Q3 2023.
  • In the last 3 years, Keros Therapeutics' EBT Margin had a median value of -13,648.45% in 2024 and averaged -84,785.07%.
  • Per our database at Business Quant, Keros Therapeutics' EBT Margin spiked by 143,170,000bps in 2021 and then plummeted by 158,363,437bps in 2022.
  • Quarterly analysis of 5 years shows Keros Therapeutics' EBT Margin stood at -24.70% in 2021, then plummeted by 158,363,437bps to -134.37% in 2022, then reached -32,486.01% in 2023, then skyrocketed by 3,098,286bps to -1,503.16% in 2024, then soared by 1,358,742bps to -61.03% in 2025.
  • Its last three reported values are -61.03% in Q3 2025, -181.19% for Q2 2025, and 75.03% during Q1 2025.